Various vaccination therapies using tumour-associated antigen (TAA)-derived peptides, autologous tumour lysates and tumour lysate-loaded dendritic cells have been developed to date.2 We conducted peptide-vaccination trials using TAA-derived peptides of SYT–SSX junctional peptides derived from specific chromosomal translocation for synovial sarcoma, papillomavirus-binding factor (PBF) for osteosarcoma and survivin for various carcinomas.3,4 Although immune responses against the vaccinated peptides were frequently observed, the objective clinical response rates were low. This evidence concerns the gene BIRC5 and neoplasm.